Larimar Therapeutics, Inc. (LRMR) Tops Q2 EPS by 1c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q2 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens
• Union Pacific (UNP) Reiterated at Market Outperform by Citizens - Most Attractive in Rail Group